Hormonal
IL-1β antagonists (e.g., anakinra, gevokizumab) improve glycemia and beta-cell function in type 2 diabetes, but their effect on cardiovascular events is still being determined in large trials.
Blocking specific inflammatory proteins like IL-1β can improve blood sugar control and protect beta-cells in type 2 diabetes. While promising, these treatments are currently biologics (injections) and are still being studied for their long-term impact on heart disease. They represent a targeted approach to the inflammatory component of diabetes.
Improved glycemia and β cell secretory function and reduced markers of systemic inflammation were demonstrated in a proof-of-concept trial of 70 patients with T2D randomized to receive daily IL-1Ra (anakinra) or placebo for 13 weeks.
Why this rating
Proof-of-concept trials show benefit, but large outcome trials (CANTOS) are ongoing or inconclusive for glycemic effects.
Source
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Allison B. Goldfine et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci88884
More from this paper
- Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.Strong
- Obesity-related sub-acute chronic inflammation acts as a pathologic mediator for both type 2 diabetes and atherosclerotic cardiovascular disease, with inflammatory markers like CRP predicting risk independently of weight.Good
- Salsalate, a non-acetylated salicylate, lowers blood glucose and triglycerides in type 2 diabetes by activating AMPK and inhibiting NF-κB, but its effect on cardiovascular plaque progression is unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →